Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer.

ABSTRACT: Background: Claudin-18.2 (CLDN18.2) has emerged as a promising therapeutic target for gastric cancer due to its frequent and specific expression in malignant lesions. Dendritic cell (DC)-based vaccines represent a potent strategy for inducing antitumor immunity; however, their efficacy against solid tumors, such as gastric cancer, remains challenging. Methods: We developed a lentiviral vector encoding human CLDN18.2 (Lv-CLDN18.2) to generate antigen-loaded DC vaccines. In vitro, human monocyte-derived DCs were transduced and co-cultured with autologous T cells to induce cytotoxic T lymphocytes (CTLs). CTL function was assessed by flow cytometry, cytokine ELISA, and cytotoxicity assays against CLDN18.2-positive gastric cancer cells. In vivo, the therapeutic efficacy of the DC

SUBMITTER: Zheng B 

PROVIDER: S-EPMC12897038 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature